Secondary amyloidosis electrocardiogram: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Secondary amyloidosis}} {{CMG}}; {{AE}} {{Sahar}} ==Overview== An ECG may be helpful in the diagnosis of secondary amyloidosis. ==Electrocardiogram== * An ECG..." |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Secondary amyloidosis}} | {{Secondary amyloidosis}} | ||
{{CMG}}; {{AE}} {{Sahar}} | {{CMG}}; {{AE}} {{Sahar}} {{Shyam}} | ||
==Overview== | ==Overview== | ||
An [[ECG]] may be helpful in the diagnosis of secondary amyloidosis. | An [[ECG]] may be helpful in the diagnosis of secondary amyloidosis. Possible ECG findings associated with the diagnosis of cardiac involvement include low voltage QRS complexes, [[left ventricle|Left ventricular]] [[Hypertrophy (medical)|hypertrophy]], [[right ventricle|Right ventricular]] hypertrophy, and [[atrioventricular block]]. | ||
==Electrocardiogram== | ==Electrocardiogram== | ||
* An ECG may be helpful in the diagnosis of secondary amyloidosis. Findings on an ECG suggestive of cardiac involvement include:<ref name="Real de AsuaGalvan2014">{{cite journal|last1=Real de Asua|first1=Diego|last2=Galvan|first2=Jose Maria|last3=Filigghedu|first3=Maria Teresa|last4=Trujillo|first4=Davinia|last5=Costa|first5=Ramon|last6=Cadinanos|first6=Julen|title=Systemic AA amyloidosis: epidemiology, diagnosis, and management|journal=Clinical Epidemiology|year=2014|pages=369|issn=1179-1349|doi=10.2147/CLEP.S39981}}</ref> | * An [[ECG]] may be helpful in the [[diagnosis]] of secondary amyloidosis. Findings on an [[ECG]] suggestive of [[cardiac]] involvement include:<ref name="Real de AsuaGalvan2014">{{cite journal|last1=Real de Asua|first1=Diego|last2=Galvan|first2=Jose Maria|last3=Filigghedu|first3=Maria Teresa|last4=Trujillo|first4=Davinia|last5=Costa|first5=Ramon|last6=Cadinanos|first6=Julen|title=Systemic AA amyloidosis: epidemiology, diagnosis, and management|journal=Clinical Epidemiology|year=2014|pages=369|issn=1179-1349|doi=10.2147/CLEP.S39981}}</ref> | ||
** Voltage is lower than 5 mm in all limb leads. | ** Voltage is lower than 5 mm in all limb leads. | ||
* Other possible findings include: | |||
**[[Left ventricle|Left ventricular]] [[Hypertrophy (medical)|hypertrophy]]<ref name="pmid25743445">{{cite journal| author=Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J| title=Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. | journal=J Cardiovasc Transl Res | year= 2015 | volume= 8 | issue= 2 | pages= 117-27 | pmid=25743445 | doi=10.1007/s12265-015-9613-9 | pmc=4382536 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25743445 }} </ref> | |||
**[[Right ventricle|Right ventricular]] hypertrophy | |||
**[[Left atrium|Left atrial]] abnormalities | |||
*Pathological [[Q waves]]<ref name="pmid25743445">{{cite journal| author=Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J| title=Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. | journal=J Cardiovasc Transl Res | year= 2015 | volume= 8 | issue= 2 | pages= 117-27 | pmid=25743445 | doi=10.1007/s12265-015-9613-9 | pmc=4382536 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25743445 }} </ref> | |||
**[[Atrioventricular block]]: [[Atrioventricular block|AV block]] occur due to deposition of amyloid fibrils in the conduction [[Tissue (biology)|tissue]]. | |||
* [[Cardiac]] involvement rarely occurs in the secondary amyloidosis and other possible cause should be ruled out first.<ref name="PapaLachmann2018">{{cite journal|last1=Papa|first1=Riccardo|last2=Lachmann|first2=Helen J.|title=Secondary, AA, Amyloidosis|journal=Rheumatic Disease Clinics of North America|volume=44|issue=4|year=2018|pages=585–603|issn=0889857X|doi=10.1016/j.rdc.2018.06.004}}</ref> | * [[Cardiac]] involvement rarely occurs in the secondary amyloidosis and other possible cause should be ruled out first.<ref name="PapaLachmann2018">{{cite journal|last1=Papa|first1=Riccardo|last2=Lachmann|first2=Helen J.|title=Secondary, AA, Amyloidosis|journal=Rheumatic Disease Clinics of North America|volume=44|issue=4|year=2018|pages=585–603|issn=0889857X|doi=10.1016/j.rdc.2018.06.004}}</ref> | ||
Latest revision as of 19:35, 7 November 2019
|
Secondary amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Secondary amyloidosis electrocardiogram On the Web |
|
American Roentgen Ray Society Images of Secondary amyloidosis electrocardiogram |
|
Risk calculators and risk factors for Secondary amyloidosis electrocardiogram |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2] Shyam Patel [3]
Overview
An ECG may be helpful in the diagnosis of secondary amyloidosis. Possible ECG findings associated with the diagnosis of cardiac involvement include low voltage QRS complexes, Left ventricular hypertrophy, Right ventricular hypertrophy, and atrioventricular block.
Electrocardiogram
- An ECG may be helpful in the diagnosis of secondary amyloidosis. Findings on an ECG suggestive of cardiac involvement include:[1]
- Voltage is lower than 5 mm in all limb leads.
- Other possible findings include:
- Left ventricular hypertrophy[2]
- Right ventricular hypertrophy
- Left atrial abnormalities
- Pathological Q waves[2]
- Atrioventricular block: AV block occur due to deposition of amyloid fibrils in the conduction tissue.
- Cardiac involvement rarely occurs in the secondary amyloidosis and other possible cause should be ruled out first.[3]
References
- ↑ Real de Asua, Diego; Galvan, Jose Maria; Filigghedu, Maria Teresa; Trujillo, Davinia; Costa, Ramon; Cadinanos, Julen (2014). "Systemic AA amyloidosis: epidemiology, diagnosis, and management". Clinical Epidemiology: 369. doi:10.2147/CLEP.S39981. ISSN 1179-1349.
- ↑ 2.0 2.1 Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J (2015). "Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis". J Cardiovasc Transl Res. 8 (2): 117–27. doi:10.1007/s12265-015-9613-9. PMC 4382536. PMID 25743445.
- ↑ Papa, Riccardo; Lachmann, Helen J. (2018). "Secondary, AA, Amyloidosis". Rheumatic Disease Clinics of North America. 44 (4): 585–603. doi:10.1016/j.rdc.2018.06.004. ISSN 0889-857X.